Tocagen Inc (NASDAQ:TOCA) saw a significant growth in short interest in the month of December. As of December 29th, there was short interest totalling 1,208,548 shares, a growth of 38.7% from the December 15th total of 871,611 shares. Currently, 7.1% of the shares of the company are sold short. Based on an average daily volume of 177,614 shares, the short-interest ratio is currently 6.8 days.
Several institutional investors have recently modified their holdings of the business. New York State Common Retirement Fund acquired a new position in shares of Tocagen in the second quarter worth about $108,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Tocagen in the second quarter worth about $165,000. BBR Partners LLC acquired a new position in shares of Tocagen in the third quarter worth about $181,000. California State Teachers Retirement System acquired a new position in shares of Tocagen in the second quarter worth about $179,000. Finally, Teachers Advisors LLC acquired a new position in shares of Tocagen in the second quarter worth about $181,000. Institutional investors and hedge funds own 36.22% of the company’s stock.
Separately, Zacks Investment Research downgraded shares of Tocagen from a “hold” rating to a “sell” rating in a research report on Wednesday, September 27th.
Tocagen (NASDAQ:TOCA) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. equities analysts anticipate that Tocagen will post -2.66 EPS for the current fiscal year.
Tocagen Company Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.